Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Investigators at St. John’s University have published preclinical data regarding their endothelin-1 receptor (ETRA) antagonist HJP-272 for the potential treatment of cancer.
Mycobacterium abscessus, a nontuberculous mycobacterium, is a significant cause of chronic pulmonary infections, particularly in individuals with compromised immune systems or structural lung conditions, such as cystic fibrosis.
Microglia are the brain’s innate immune cells that maintain brain health and play a key role in Alzheimer's disease (AD). Triggering receptor expressed on myeloid cells 2 (TREM2) acts as a regulator of microglial cells and restores neuronal functioning.
Cptx GmbH’s QUIET-CAR collaborative project with Nanocell Therapeutics Inc. has been awarded a Eurostars Grant from the EU through the Horizon Europe program and Eureka Network. The QUIET-CAR project aims to develop targeted lipid nanoparticles carrying novel immune-silent single-stranded DNA (ssDNA) for in vivo CAR T therapy.
Researchers from the University of Tennessee and collaborating institutions have investigated in preclinical models the use of an oncolytic herpes simplex virus (oHSV) armed with the immune-stimulating cytokine interleukin-12 (IL-12) as a potential treatment for glioblastoma. They published their results in Molecular Therapy: Oncology.
Researchers from Ovid Therapeutics Inc. presented preclinical efficacy data on the combination of OV-329, a small-molecule inhibitor of the mitochondrial GABA aminotransferase (GABA-AT) enzyme, with docetaxel in a murine intracardiac model of triple-negative breast cancer (TNBC).
Etern Therapeutics (Wuxi) Co. Ltd. has divulged polycyclic compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of ischemia-reperfusion injury.
RSS
